C12Q2521/337

Nucleic acid cleaving enzyme-based biosensor and methods of use thereof

This disclosure relates to biosensors, and in particular, biosensors based on nucleic acid cleaving enzymes such as ribonucleotide-cleaving DNAzymes for the detection of analytes, and methods of use.

Nucleic acid cleaving enzyme-based biosensor and methods of use thereof

This disclosure relates to biosensors, and in particular, biosensors based on nucleic acid cleaving enzymes such as ribonucleotide-cleaving DNAzymes for the detection of analytes, and methods of use.

Particle-nucleic acid conjugates and therapeutic uses related thereto
09803197 · 2017-10-31 · ·

This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analytes.

Particle-nucleic acid conjugates and therapeutic uses related thereto
09803197 · 2017-10-31 · ·

This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analytes.

Nucleic acid element candidate molecule and screening method for screening for nucleic acid element for target analysis using the same

The present invention provides a novel nucleic acid element candidate molecule for use in screening for a nucleic acid element for target analysis and a novel screening method for screening for a nucleic acid element for target analysis using the same. The candidate molecule according to the present invention is a molecule for screening for a nucleic acid element for target analysis, being the following single-stranded nucleic acid (I): (I) a single-stranded nucleic acid comprising a catalyst sequence (D), a blocking sequence (B), and a binding sequence (A) that binds to a target, linked in this order. The blocking sequence (B) is complementary to a partial region (Dp) in the catalyst sequence (D). A terminal region (Ab) on the blocking sequence (B) side in the binding sequence (A) is complementary to a flanking region (Df) of the partial region (Dp) in the catalyst sequence (D) and is complementary to a terminal region (Af) on the side opposite to the blocking sequence (B) side in the binding sequence (A).

Nucleic acid element candidate molecule and screening method for screening for nucleic acid element for target analysis using the same

The present invention provides a novel nucleic acid element candidate molecule for use in screening for a nucleic acid element for target analysis and a novel screening method for screening for a nucleic acid element for target analysis using the same. The candidate molecule according to the present invention is a molecule for screening for a nucleic acid element for target analysis, being the following single-stranded nucleic acid (I): (I) a single-stranded nucleic acid comprising a catalyst sequence (D), a blocking sequence (B), and a binding sequence (A) that binds to a target, linked in this order. The blocking sequence (B) is complementary to a partial region (Dp) in the catalyst sequence (D). A terminal region (Ab) on the blocking sequence (B) side in the binding sequence (A) is complementary to a flanking region (Df) of the partial region (Dp) in the catalyst sequence (D) and is complementary to a terminal region (Af) on the side opposite to the blocking sequence (B) side in the binding sequence (A).

Target detection and signal amplification

The present invention relates to compositions and methods for the detection of target molecules, and the amplification of detectable signals generated by detection assays. More specifically, the present invention relates to methods utilizing catalytic nucleic acid enzymes to generate and/or amplify a signal indicative of the presence of target molecules (e.g. nucleic acids and proteins), and compositions for use in the methods.

Target detection and signal amplification

The present invention relates to compositions and methods for the detection of target molecules, and the amplification of detectable signals generated by detection assays. More specifically, the present invention relates to methods utilizing catalytic nucleic acid enzymes to generate and/or amplify a signal indicative of the presence of target molecules (e.g. nucleic acids and proteins), and compositions for use in the methods.

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences, and includes detection by colorimetric and/or fluorescence shifts. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences, and includes detection by colorimetric and/or fluorescence shifts. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.